DIOGENX
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
DIOGENX
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.diogenx.com
Total Employee:
1+
Status:
Active
Total Funding:
4.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Google Universal Analytics Font Awesome Apache
Similar Organizations
Axcella
Axcella is a biotechnology company providing therapeutics development solutions.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF T1D Fund
JDRF T1D Fund investment in Seed Round - DiogenX
AdBio partners
AdBio partners investment in Seed Round - DiogenX
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - DiogenX
Official Site Inspections
http://www.diogenx.com
- Host name: cluster029.hosting.ovh.net
- IP address: 51.91.236.255
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
